HF
IMRX icon

HRT Financial’s Immuneering IMRX Stock Holding History

HRT Financial’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42,456
Closed -$223K – 4751
2026
Q1 		$223K Buy
+42,456
New +$218K ﹤0.01% 3124
2024
Q3 		– Sell
-21,364
Closed -$27K – 2758
2024
Q2 		$27K Buy
+21,364
New +$35.1K ﹤0.01% 1905

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

HRT Financial's IMRX Position: Q2 2026 in Review

HRT Financial sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 42,456 shares — an estimated $223K sold.

HRT Financial first reported a position in IMRX in Q2 2024 and held it in 2 quarters. The position peaked at $223K in Q1 2026. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • HRT Financial reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 42,456 Immuneering shares in Q2 2026, an estimated $223K.
  • HRT Financial first reported a position in Immuneering in Q2 2024 and held it in 2 quarters.
  • HRT Financial's Immuneering position peaked at $223K in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.